Skip to main content

ORIGINAL RESEARCH article

Front. Neurol.
Sec. Headache and Neurogenic Pain
Volume 16 - 2025 | doi: 10.3389/fneur.2025.1547893

Sex-related differences in the association between migraine, COVID-19, and long COVID: A population-based cohort

Provisionally accepted
  • 1 Division of Pharmacology and Cardiovascular Medicine, Department of Internal Medicine, Erasmus Medical Center, Rottersdam, Netherlands
  • 2 Institute of Public Health, Charité ー Universitätsmedizin Berlin, Berlin, Germany

The final, formatted version of the article will be published soon.

    Coronavirus disease 2019 (COVID-19),caused by the SARS-CoV-2 virus,placed unprecedented pressure on public health systems due to its mortality and global panic–and later due to long COVID challenges.One of these long COVID symptoms, headache, often resembles migraine-like features.Migraine shares similarities with COVID-19 and long COVID, yet the influence of sex is understudied.Our primary objective was to study the interrelationship between COVID-19 and migraine prevalence, while considering sex differences.The secondary objective was to examine how long COVID symptoms (headache,anosmia,memory,and concentration problems) affect males and females with and without COVID-19 and migraine.All analyses were conducted using Lifelines, a prospective cohort study in the northern Netherlands.Baseline characteristics (2006–2014),self-reported migraine diagnoses (until 2021),and questionnaires on COVID-19 and long COVID symptoms (2020-2022) were collected.Logistic regression analyses were conducted to study the association between lifetime migraine and current SARS-CoV-2 infections while adjusting for age, sex, diet, educational attainment, activity, and smoking.Descriptive and sex-stratified analyses were conducted on long COVID symptoms.A total of 150,507individuals were included, of which 29,680 (19.7%) reported migraine and 120,827 (80.3%) not.A total of 1867individuals with migraine (6.3% of individuals with migraine, 44.0 years [IQR 36.1–50.3]) and 6797individuals without migraine (5.6% of individuals without migraine, 44.4 years [IQR 35.3–52.2]) reported to be SARS-CoV-2 infected.The majority of individuals with migraine consisted of females (77.0% of those with migraine versus 54.0% of those without migraine).The adjusted odds of having SARS-CoV-2 infections was 6.3% higher among those with (a history of) migraine compared with individuals without migraine in the logistic regression model (OR=1.06, 95% CI 1.01–1.12). A slightly higher OR was observed in females (OR=1.08, 95% CI 1.02–1.15), and the association was not apparent in males (OR=1.00, 95% CI 0.88–1.12).Secondary analyses revealed that individuals with both migraine and COVID-19, and females in particular, were the most frequently bothered by long COVID symptoms headache, anosmia, concentration, and memory problems. Individuals with none of these diseases were the least bothered.Individuals with migraine,especially females, are slightly more likely to report and/or contract COVID-19. Those with both conditions report long COVID symptoms more frequently, suggesting a shared vulnerability/pathophysiology.This may indicate the need for clinical surveillance of migraine patients recovering from COVID-19.

    Keywords: Migraine, COVID-19, Long Covid, Headache, Anosmia, Memory, concentration, sex differences

    Received: 18 Dec 2024; Accepted: 07 Feb 2025.

    Copyright: © 2025 Al-Hassany, MaassenVanDenBrink and Kurth. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Linda Al-Hassany, Division of Pharmacology and Cardiovascular Medicine, Department of Internal Medicine, Erasmus Medical Center, Rottersdam, Netherlands
    Antoinette - MaassenVanDenBrink, Division of Pharmacology and Cardiovascular Medicine, Department of Internal Medicine, Erasmus Medical Center, Rottersdam, Netherlands

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.